News is a concise, evidence-aware briefing on what matters in healthcare—new trials, guideline changes, drug approvals, device safety, and health-policy shifts.
This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.
Cencora plans to spend $1 billion over the next five years to expand its operations in the U.S., including opening a second national distribution center in Ohio.
Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite
AstraZeneca is pouring $136 million more into the expansion of an inhalants production base in China, bringing its total investment at the site to $886 million.
Teva issued a voluntary recall of 580,844 bottles of the widely used blood pressure medication prazosin hydrochloride, citing unacceptable levels of potentially cancer-causing impurities.
Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection
CSL Seqirus, the vaccine unit of Australian biotech CSL, signed a pact to provide Saudi Arabia with cell-based influenza shots and to help establish its production in-country. The move comes as part
Eli Lilly has revealed a plan to spend $1.2 billion to upgrade its plant in Carolina, Puerto Rico. The investment will add 100 manufacturing jobs and bolster the company’s capacity to produce
The FDA has issued another complete response letter to Regeneron over its high-dose Eylea due to unresolved issues at a Novo Nordisk manufacturing plant. The company, however, is making progress in lining